Joint Centers of Excellence Program
Placeholder

Development of Novel Nano-Formulations to Combat MRSA Infection

Reactive oxygen species (ROS) are produced as part of aerobic metabolism and play multiple roles in normal cell signaling and homeostasis; as a consequence their production is tightly regulated. However, this delicate balance is disrupted in pathological processes causing oxidative stress and inflammation, which are involved in multidrug-resistant bacterial pathogens such as the highly-virulent methicillin-resistant Staphylococcus aureus (MRSA). Novel biotechnologies that are selectively responsive to ROS imbalances have the potential to help elucidate and treat MRSA. Therefore, therapeutic and diagnostic delivery systems responsive to ROS concentrations characteristic of oxidative stress and inflammation could advance biomedical inquiry, diagnostics, and therapeutics.